R1	Has_value Arg1:T1 Arg2:T2	
R2	Has_multiplier Arg1:T8 Arg2:T9	
R3	Has_multiplier Arg1:T10 Arg2:T11	
R4	Has_value Arg1:T12 Arg2:T13	
R5	Has_value Arg1:T19 Arg2:T20	
*	OR T15 T16 T17 T18
R6	Subsumes Arg1:T14 Arg2:T15	
*	OR T12 T14
R7	Has_index Arg1:T27 Arg2:T28	
R8	Has_temporal Arg1:T26 Arg2:T27	
*	OR T30 T31 T32 T33
R9	Subsumes Arg1:T29 Arg2:T30	
R10	Has_qualifier Arg1:T29 Arg2:T35	
R11	Has_temporal Arg1:T29 Arg2:T36	
R12	Has_index Arg1:T36 Arg2:T37	
T1	Person 0 4	Aged
T2	Value 5 10	25-80
T3	Non-query-able 25 91	Subjects older than 80 will be allowed at the discretion of the PI
T4	Person 94 104	Ambulatory
T5	Non-query-able 106 180	defined as able to ambulate at least 10 meters, with or without assistance
T6	Condition 206 208	PD
T7	Measurement 222 267	United Kingdom Brain Bank diagnostic criteria
T8	Condition 288 300	micturitions
T9	Multiplier 277 287;301 313	At least 8 per 24 hours
T10	Condition 330 346	urgency episodes
T11	Multiplier 319 329;347 363	At least 3 per 3-day diary.
T12	Measurement 367 377	MoCA score
T13	Value 378 395	between 19 and 28
T14	Procedure 435 454	cognitive enhancers
T15	Drug 456 465	donepezil
T16	Drug 467 479	rivastigmine
T17	Drug 481 490	memantine
T18	Drug 492 503	galantamine
T19	Measurement 507 517	MoCA score
T20	Value 518 535	between 19 and 29
T23	Informed_consent 563 726	Provide informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care
T24	Informed_consent 729 832	Be cognitively capable, in the opinion of investigator, to understand and provide such informed consent
T25	Post-eligibility 835 1012	Be cognitively capable to complete the required questionnaires and assessments, OR have a care partner who is willing and capable to assist them in the completion of these tasks
T26	Drug 1041 1068	antiparkinson's medications
T27	Temporal 1069 1104	at least 30 days prior to screening
T28	Reference_point 1095 1104	screening
T29	Procedure 1191 1210	cognitive enhancers
T30	Drug 1212 1221	donepezil
T31	Drug 1223 1235	rivastigmine
T32	Drug 1237 1246	memantine
T33	Drug 1248 1259	galantamine
T35	Qualifier 1273 1284	stable dose
T36	Temporal 1285 1320	at least 30 days prior to screening
T37	Reference_point 1311 1320	screening
